Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients
Year: 2020
Type: article
Abstract: There are currently limited data on the epidemiology, clinical manifestations, and optimal management of Coronavirus Disease 2019 (COVID-19) in hematopoietic cell transplantation and cellular therapy recipients. Given the experience with other respiratory viruses, we anticipate that patients may develop severe clinical disease and thus provide the following general principles for cancer centers across the nation. These guidelines were developed by members of the American Society for Transplantation and Cellular Therapy Infectious Diseases Special Interest Group. Specific practices may vary depending on local epidemiology and testing capacity, and the guidance provided in this document may change as new information becomes available.
Institutions: Seattle Children's Hospital, University of Washington, Fred Hutch Cancer Center, University of Colorado Denver, The University of Texas MD Anderson Cancer Center, City Of Hope National Medical Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Wexner Medical Center, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Seattle Cancer Care Alliance, Levine Cancer Institute
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W3045676021